Fiche publication
Date publication
juillet 2019
Journal
Expert review of gastroenterology & hepatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Peyrin-Biroulet L, Danese S, Cummings F, Atreya R, Greveson K, Pieper B, Kang T
Lien Pubmed
Résumé
: The purpose of this review is to highlight the role of biosimilars in early treatment in IBD and introduce ways to facilitate a patient-centric switching process through multidisciplinary approach. : We summarize existing scientific literature related to the role of biosimilars in inflammatory bowel disease in terms of early treatment and cost-saving and implementing switching process. : Use of anti-TNF biosimilars in patients has the potential for large drug-acquisition cost-saving, which can be reinvested into early treatment. Managed switched programs for adalimumab can add further benefits in the future.
Mots clés
Adalimumab, Crohn’s disease, biosimilars, infliximab, tumor necrosis factor
Référence
Expert Rev Gastroenterol Hepatol. 2019 Jul 26;:1-8
